Lachlan R. Gray, Gilda Tachedjian, Anne M. Ellett, Michael J. Roche, Wan-Jung Cheng, Gilles J. Guillemin, Bruce J. Brew, Stuart G. Turville, Steve L. Wesselingh, Paul R. Gorry, Melissa J. Churchill

The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes


© 2013 Gray et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Originally published at:
http://doi.org/10.1371/journal.pone.0062196

PERMISSIONS

http://creativecommons.org/licenses/by/4.0/

http://hdl.handle.net/2440/97108
The NRTIs Lamivudine, Stavudine and Zidovudine Have Reduced HIV-1 Inhibitory Activity in Astrocytes

Lachlan R. Gray1,2, Gilda Tachedjian1,3,4, Anne M. Ellett1, Michael J. Roche1, Wan-Jung Cheng1, Gilles J. Guillemin7, Bruce J. Brew7, Stuart G. Turville8, Steve L. Wesselingh1,9, Paul R. Gorry1,5,6, Melissa J. Churchill1,3,4

1 Centre for Virology, Burnet Institute, Melbourne, Victoria, Australia, 2 Department of Biochemistry and Molecular Biology, Monash University, Victoria, Australia, 3 Department of Microbiology, Monash University, Victoria, Australia, 4 Department of Medicine, Monash University, Victoria, Australia, 5 Department of Infectious Diseases, Monash University, Victoria, Australia, 6 Department of Microbiology and Immunology, University of Melbourne, Melbourne, Victoria, Australia, 7 Department of Neurology, and St. Vincent’s Centre for Applied Medical Research, St. Vincent’s Hospital, Darlinghurst, New South Wales, Australia, 8 The Kirby Institute, Darlinghurst, New South Wales, Australia, 9 South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia

Abstract

HIV-1 establishes infection in astrocytes and macroage-lineage cells of the central nervous system (CNS). Certain antiretroviral therapy (Neuro-cART) regimens, but their relative activity in the different susceptible CNS cell populations is unknown. Here, we determined the HIV-1 inhibitory activity of CNS-penetrating ARVs in astrocytes and macroage-lineage cells. Primary human fetal astrocytes (PFA) and the SVG human astrocyte cell line were used as an in vitro model for astrocyte infection, and monocyte-derived macrophages (MDM) were used as an in vitro model for infection of macroage-lineage cells. The CNS-penetrating ARVs tested were the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir (ABC), lamivudine (3TC), stavudine (d4T) and zidovudine (ZDV), the non-NRTIs efavirenz (EFV), etravirine (ETR) and nevirapine (NVP), and the integrase inhibitor raltegravir (RAL). Drug inhibition assays were performed using single-round HIV-1 entry assays with luciferase viruses pseudotyped with HIV-1 YU-2 envelope or vesicular stomatitis virus G protein (VSV-G). All the ARVs tested could effectively inhibit HIV-1 infection in macrophages, with EC90s below concentrations known to be achievable in the cerebral spinal fluid (CSF). Most of the ARVs had similar potency in astrocytes, however the NRTIs 3TC, d4T and ZDV had insufficient HIV-1 inhibitory activity in astrocytes, with EC90s 12-, 187- and 110-fold greater than achievable CSF concentrations, respectively. Our data suggest that 3TC, d4T and ZDV may not adequately target astrocyte infection in vivo, which has potential implications for their inclusion in Neuro-cART regimens.

Introduction

Human immunodeficiency virus type 1 (HIV-1) penetrates the central nervous system (CNS) during acute infection or sometime shortly thereafter. Later in the course of HIV-1 disease it frequently causes encephalitis (HIVE), HIV-associated dementia (HAD) or less severe HIV-associated neurocognitive disorders (HAND) [1]. While it is the macroage-lineage cells of the CNS that support productive HIV-1 replication, specifically the perivascular macrophages and microglia [1,2], astrocytes undergo a restricted infection [3–5]. Nonetheless, recent studies have demonstrated that up to 19% of astrocytes can become infected in patients with the most severe HAD and HIVE, and therefore astrocytes potentially represent a significant viral reservoir [6]. Furthermore, whilst astrocyte infection is restricted, their infection results in cellular dysfunction. This is associated with changes in gene expression [7], loss of neuronal support, reduced ability to maintain glutamate levels and loss of integrity of the blood-brain barrier (BBB) [1,4], likely contributing to the development of HAND.

Certain antiretroviral drugs (ARVs) have been shown to have potentially superior CNS efficacy, as determined by the CNS penetration-effectiveness (CPE) scoring system, which is based on available drug concentrations in the cerebrospinal fluid (CSF) [8,9] and clinical data showing improved neurocognitive outcomes. These ARVs include the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir (ABC), emtricitabine (FTC), lamivudine (3TC), stavudine (d4T) and zidovudine (ZDV), the non-NRTIs efavirenz (EFV), delavirdine (DVL), etravirine (ETR) and nevirapine (NVP), the protease inhibitors (PIs) indinavir (IDV), darunavir (DRV), lopinavir (LPV), the CCR5 antagonist maraviroc (MVC), and the integrase inhibitor raltegravir (RAL). Because of their favorable CNS penetration, these agents are used in so-called “neurologically active combined antiretroviral therapy”, or Neuro-cART.
in regimen, with the premise that their superior bioavailability in the CNS would be optimal for treating CNS infection [10,11].

However, the relative activity of CNS-penetrating ARVs in the different susceptible CNS cell types has yet to be determined. Furthermore, whether any or all of these agents have HIV-1 inhibitory activity in astrocytes at physiologically relevant concentrations is unknown.

In this study, we determined the HIV-1 inhibitory activity of the NRTIs ABC, 3TC, d4T and ZDV, the non-NRTIs EFV, ETR and NVP, and the integrase inhibitor RAL in cellular models of brain macrophage-lineage cells and astrocytes, with comparison to peripheral blood mononuclear cells (PBMC). Our results show that whilst all the ARVs tested have potent inhibitory activity in macrophages and PBMC at physiologically relevant concentrations, the NRTIs 3TC, d4T and ZDV have inadequate inhibitory activity in astrocytes, with 90% inhibitory concentrations (EC90) exceeding those achievable in the CSF. These results suggest that 3TC, d4T and ZDV may not effectively target astrocyte infection in vivo, which has potential implications for their inclusion in Neuro-cART regimens.

Materials and Methods

Antiretroviral Drugs

The characteristics of the ARVs used in the study are summarized in Table 1 and all were prepared as 10 mM stocks in DMSO except for RAL, which was prepared in water. The ARVs were chosen to predominantly represent those used in current Neuro-cART regimens [12], and consisted of NRTIs, NNRTIs and integrase inhibitors. While protease inhibitors are currently used in Neuro-cART, we were unable to analyze them in this study because of the single round virus assay used here and the nature of our luciferase readout.

Human ethics approval

Human fetal brain tissue and PBMC were obtained following informed written consent from all participants in the study. This has been respectively approved by the Human Ethics Committees from St Vincent’s Hospital (HREC 08284) and from the University of New South Wales (UNSW Ethic approval HREC 03187).

Table 1. Biological and pharmacological properties of the ARVs.

<table>
<thead>
<tr>
<th>ARV</th>
<th>Abbreviation</th>
<th>ARV Classa</th>
<th>Neuro-cART</th>
<th>ARV concentrations (µM)</th>
<th>Highest non-toxic concentration of ARV (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Plasmab</td>
<td>CSFa</td>
</tr>
<tr>
<td>Abacavir</td>
<td>ABC</td>
<td>NRTI</td>
<td>Yes</td>
<td>5.2–10.9</td>
<td>0.5–1.8</td>
</tr>
<tr>
<td>Lamivudine</td>
<td>3TC</td>
<td>NRTI</td>
<td>Yes</td>
<td>4.4–8.7</td>
<td>0.05–1.1</td>
</tr>
<tr>
<td>Stavudine</td>
<td>d4T</td>
<td>NRTI</td>
<td>Yes</td>
<td>3.4–6.4</td>
<td>0.2–0.4</td>
</tr>
<tr>
<td>Zidovudine</td>
<td>ZDV</td>
<td>NRTI</td>
<td>Yes</td>
<td>4.5–6.7</td>
<td>0.1–0.4</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>EFV</td>
<td>NNRTI</td>
<td>Yes</td>
<td>9.2–16.6</td>
<td>0.01–0.09</td>
</tr>
<tr>
<td>Etravirine</td>
<td>ETR</td>
<td>NNRTI</td>
<td>Yes</td>
<td>0.2–0.4</td>
<td>0.01–0.02</td>
</tr>
<tr>
<td>Nevirapine</td>
<td>NVP</td>
<td>NNRTI</td>
<td>Yes</td>
<td>7.5–16.9</td>
<td>1.3–10.9</td>
</tr>
<tr>
<td>Raltegravir</td>
<td>RAL</td>
<td>INI</td>
<td>Yes</td>
<td>0.1–4.5</td>
<td>0.01–0.3</td>
</tr>
</tbody>
</table>

aNRTI, Nucleoside reverse transcriptase inhibitor; NNRTI, Non-nucleoside reverse transcriptase inhibitor; INI, Integrase inhibitor.

bThe in vivo plasma concentration range [36].

cThe in vivo cerebrospinal fluid (CSF) concentration range [36].

dIC50 of inhibitory activity of ARVs in astrocytes at physiologically relevant concentration [36].

eCPE, CNS penetration-effectiveness (The scale is from 1 to 4, with 4 being the most favorable CNS penetration-effectiveness) [12].

Conversion factor (M-CSF).

Cell lines and primary cells

The SVG astrocyte cell line [13] was cultured in Minimum Essential Medium (MEM) supplemented with 20% (vol/vol) heat-inactivated fetal calf serum (HI-FCS), 100 µg/ml of penicillin and streptomycin, and 2 mM of GlutaMAX (Invitrogen, USA). Primary human fetal astrocytes (PFA) were prepared as previously described [14], and were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% (vol/vol) HI-FCS, 100 µg/ml of penicillin and streptomycin, and 2 mM of GlutaMAX (Invitrogen). PBMC were purified from the blood of healthy HIV-1-negative donors, stimulated with 5 µg/ml of phytohemagglutinin (Sigma, USA) for 3 days, and cultured in RPMI 1640 medium supplemented with 10% (vol/vol) HI-FCS, 100 µg/ml of penicillin and streptomycin, and 20 U/ml of interleukin-2 (Roche, Switzerland). Monocyte-derived macrophages (MDM) were produced from elutriated monocytes that were cultured for 5 days in RPMI 1640 medium supplemented with 10% (vol/vol) pooled human sera, 100 µg/ml of penicillin and streptomycin, and 12.5 ng/ml of macrophage colony-stimulating factor (M-CSF).

Production and quantitation of Env-pseudotyped luciferase reporter viruses

Env-pseudotyped luciferase reporter viruses were produced by transfection of 293T cells with pCMVΔpAΔenvpA, pHIV-1Luc, and either pcDNA3-VSVG or pSVIII-YU2 Env plasmids using Lipofectamine 2000 (Invitrogen) at a ratio of 1:3:1, as described previously [15–17]. Viruses pseudotyped with the CCR5-using HIV-1 YU-2 envelope glycoproteins were used for infections of PBMC and MDM, whereas SVG cells and PFA were infected with viruses pseudotyped with the vesicular stomatitis virus G protein (VSV-G) in order to achieve sufficient levels of viral entry for the inhibition assays. The supernatants containing virus pseudotypes.
were harvested 48 h later, filtered through 0.45 μm filters, titrated on each of the different cell types (TCID\textsubscript{50} values were calculated), and stored at −80°C.

**Cell viability assay**
ARV cytotoxicity was assessed in all cell types at 72 h post-drug exposure using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, USA), according to the manufacturer’s protocol.

**Virus inhibition assays**
Assays were performed in all cell types in the presence of titrating concentrations of ARV. 5,000 SVG, 2,500 PFA, 200,000 PBMC, or 50,000 MDM cells/well were seeded into triplicate wells of 96-well plates. Twenty-four hours later, the culture medium was removed and replaced with medium containing the ARV or DMSO (0.5% vol/vol), and equivalent TCID\textsubscript{50} infectious units of luciferase reporter virus were added to the cells. After a 16 h incubation at 37°C, the initial viral inoculum was removed and replaced with culture medium containing the same ARV or DMSO (0.5% vol/vol) concentrations. At 72 h post infection, the medium was aspirated, the cells were lysed and HIV-1 infection measured using the Luciferase Assay System (Promega) according to manufacturer’s instructions. Luminescence was measured using a FLUOStar Optima microplate reader (BMG Labtech, Germany). Inhibition curves and the 50% (EC\textsubscript{50}) and 90% (EC\textsubscript{90}) effective concentrations were determined by nonlinear regression analysis as previously described [16–18], using GraphPad Prism software (version 5.0d; GraphPad Software, USA).

**Results**

**Inhibitory activity of CNS-penetrating ARVs in CNS cell models**
We first evaluated the cellular cytotoxicity of the ARVs in the cell types studied. The characteristics of the ARVs, including their achievable plasma and CSF concentrations, inhibitory concentration ranges, CPE scores, and whether they have been used in Neuro-cART regimens are summarized in Table 1. None of the ARVs showed evidence of cytotoxicity at the highest concentrations tested in the virus inhibition assays (Table 1). Mitochondrial toxicity of the ARVs was not tested. Next, we evaluated the inhibitory activity of all the CNS-penetrating ARVs in cell models that represent brain astrocytes (the SVG astrocyte cell line and PFA), and brain macrophage-lineage cells (MDM), with comparison to that in a cell model that represents activity in the peripheral blood (PBMC). MDM were chosen as a model for brain macrophage-lineage cells because cell lines for perivascular macrophages do not exist and those for microglia are particularly poor at representing \textit{in vivo} microglia. In addition, primary cells are extremely hard to obtain and difficult to culture and use. Our previous studies have shown that the HIV-1 replication characteristics in MDM recapitulate those observed in primary cultures of human fetal microglia [19], confirming their suitability as a convenient \textit{in vitro} cellular model for macrophage-lineage cells \textit{in vivo}. Virus inhibition curves are shown in Figure 1, and the EC\textsubscript{50} and EC\textsubscript{90} values are summarized in Table 2 and Table 3, respectively. Our results show that all the ARVs tested have inhibitory activity in SVG, PFA, MDM and PBMC, but with variable potencies (Tables 2 and 3). Of note, the EC\textsubscript{50} and EC\textsubscript{90} values for 3TC, d4T and ZDV were consistently higher in the SVG astrocytes and PFA compared to those in MDM and PBMC, suggesting reduced HIV-1 inhibitory activity by these particular NRTIs in astrocytes.

![Figure 1](https://example.com) **Figure 1. HIV-1 inhibitory activity of ARVs in primary cells.** Virus inhibition assays were performed in PFA (A), MDM (B) and PBMC (C) using titrating amounts of ARVs, as described in Materials and Methods. The inhibition curves were generated as described in Materials and Methods, and were used to calculate the EC\textsubscript{50} and EC\textsubscript{90} values that are shown in Tables 1 and 2, respectively. The data are a compilation of 4 independent experiments, each using cells obtained from separate independent donors, with each experiment conducted in triplicate. Shown are the means and SEM of these data. doi:10.1371/journal.pone.0062196.g001

The NRTIs d4T and ZDV have markedly reduced effectiveness in astrocytes compared to macrophages and PBMC
To better understand the apparent disparity between the inhibitory activities of 3TC, d4T and ZDV in astrocytes compared to the other cell models, we next undertook statistical analyses of the EC\textsubscript{50} and EC\textsubscript{90} values for these NRTIs in astrocytes compared to MDM and PBMC (Table 4). Here, we focussed on the results with PFA rather than SVG cells, as PFA represent the more relevant of the two cellular models for astrocytes \textit{in vivo}. These
analyses showed that the EC50 values for 3TC, d4T and ZDV in astrocytes were 8.8-, 142- and 262-fold greater than that in MDM, respectively (p < 0.01). The EC50 values for d4T and ZDV in astrocytes were 33- and 164-fold greater than that in PBMC (p < 0.01), respectively, but there was no difference for 3TC. The EC50 values for 3TC, d4T and ZDV in astrocytes were 63-, 382- and 202-fold greater than that in MDM, respectively (p < 0.01). The EC90 values for d4T and ZDV in astrocytes were 18- and 92-fold greater than that in PBMC (p < 0.01), respectively. The EC90 for 3TC in astrocytes was a modest 4.3-fold greater than that in PBMC, which neared significance. These results indicate that the NRTIs d4T and ZDV, and to a lesser extent 3TC, have reduced potency against HIV-1 in astrocytes compared to macrophages and PBMC in vitro.

3TC, d4T and ZDV EC90 values in astrocytes exceed those achieved in the CSF.

For an ARV to have effective inhibitory activity in vivo, its in vitro EC90 needs to fall below (or be equivalent to) the drug concentration that is achieved in the relevant tissue compartment [20,21]. Therefore, although the preceding analyses showed that d4T and ZDV (and to a lesser degree 3TC) have reduced in vitro HIV-1 inhibitory activity in astrocytes compared to macrophages, the central issue that may have relevance to Neuro-cART regimens is whether their elevated EC90 values in astrocytes places these concentrations above what can be achieved by the drug in the CSF. We therefore next compared the EC90 values of each ARV obtained in the different cell models to the respective concentration range achievable in the CSF (for astrocytes and MDM) or plasma (for PBMC) (Figure 2). For these comparisons, the shaded boxes in Figure 2 indicate the physiological drug concentration ranges for each ARV in the CSF (Fig. 2A, B) and plasma (Fig. 2C), and the orange triangles represent the EC90 values of each ARV in astrocytes (Fig. 2A), macrophages (Fig. 2B) and PBMC (Fig. 2C). Here, the boxes shaded green indicate where the ARV EC90 falls below the physiological drug concentration range, the boxes shaded orange indicate where the ARV EC90 falls within the physiological drug concentration range, and the boxes shaded in red indicate where the ARV EC90 exceeds the physiological concentration range. These analyses show that the NRTIs 3TC, d4T and ZDV have EC90 values in astrocytes that exceed the achievable CSF drug concentration ranges (Fig. 2A). In contrast, the NRTI ABC, the NNRTIs EFV, ETR and NVP, and the integrase inhibitor RAL have EC90 values in astrocytes that are below or within the physiological concentration ranges in the CNS (Fig. 2A), and all the ARVs have EC90 values in macrophages (Fig. 2B) and PBMC (Fig. 2C) that are below or within the

### Table 2. ARV EC50 values for inhibition of HIV-1 in different cell types.

<table>
<thead>
<tr>
<th>ARV</th>
<th>SVG (μM) +/− SE* (μM)</th>
<th>PFA (μM) +/− SE* (μM)</th>
<th>PBMC (μM) +/− SE* (μM)</th>
<th>MDM (μM) +/− SE* (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abacavir</td>
<td>0.056 +/− 0.011</td>
<td>0.004 +/− 0.001</td>
<td>0.017 +/− 0.002</td>
<td>0.001 +/− 0.003</td>
</tr>
<tr>
<td>Lamivudine</td>
<td>1.484 +/− 0.204</td>
<td>0.317 +/− 0.055</td>
<td>0.315 +/− 0.107</td>
<td>0.036 +/− 0.059</td>
</tr>
<tr>
<td>Stavudine</td>
<td>0.578 +/− 0.189</td>
<td>5.963 +/− 0.622</td>
<td>0.179 +/− 0.061</td>
<td>0.042 +/− 0.046</td>
</tr>
<tr>
<td>Zidovudine</td>
<td>0.017 +/− 0.0003</td>
<td>1.311 +/− 0.130</td>
<td>0.008 +/− 0.002</td>
<td>0.005 +/− 0.002</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>0.002 +/− 0.0000</td>
<td>0.002 +/− 0.0000</td>
<td>0.001 +/− 0.0000</td>
<td>0.001 +/− 0.0000</td>
</tr>
<tr>
<td>Etravirine</td>
<td>0.001 +/− 0.0000</td>
<td>0.001 +/− 0.0000</td>
<td>0.001 +/− 0.0000</td>
<td>0.001 +/− 0.0000</td>
</tr>
<tr>
<td>Nevirapine</td>
<td>0.045 +/− 0.0006</td>
<td>0.114 +/− 0.020</td>
<td>0.182 +/− 0.068</td>
<td>0.166 +/− 0.253</td>
</tr>
<tr>
<td>Raltegravir</td>
<td>0.004 +/− 0.0001</td>
<td>0.007 +/− 0.0001</td>
<td>0.003 +/− 0.001</td>
<td>0.016 +/− 0.010</td>
</tr>
</tbody>
</table>

*Mean 50% effective concentration ± the standard error from n = 4 independent assays.

### Table 3. ARV EC90 values for inhibition of HIV-1 in different cell types.

<table>
<thead>
<tr>
<th>ARV</th>
<th>SVG (μM) +/− SE* (μM)</th>
<th>PFA (μM) +/− SE* (μM)</th>
<th>PBMC (μM) +/− SE* (μM)</th>
<th>MDM (μM) +/− SE* (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abacavir</td>
<td>0.369 +/− 0.055</td>
<td>1.738 +/− 0.354</td>
<td>1.318 +/− 0.141</td>
<td>0.636 +/− 0.084</td>
</tr>
<tr>
<td>Lamivudine</td>
<td>43.942 +/− 4.805</td>
<td>13.451 +/− 2.315</td>
<td>3.101 +/− 0.471</td>
<td>0.214 +/− 0.156</td>
</tr>
<tr>
<td>Stavudine</td>
<td>5.775 +/− 1.466</td>
<td>74.965 +/− 7.821</td>
<td>4.261 +/− 0.645</td>
<td>0.196 +/− 0.096</td>
</tr>
<tr>
<td>Zidovudine</td>
<td>0.205 +/− 0.031</td>
<td>44.157 +/− 4.384</td>
<td>0.481 +/− 0.061</td>
<td>0.219 +/− 0.041</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>0.010 +/− 0.002</td>
<td>0.009 +/− 0.002</td>
<td>0.012 +/− 0.002</td>
<td>0.004 +/− 0.001</td>
</tr>
<tr>
<td>Etravirine</td>
<td>0.003 +/− 0.001</td>
<td>0.003 +/− 0.000</td>
<td>0.010 +/− 0.001</td>
<td>0.007 +/− 0.001</td>
</tr>
<tr>
<td>Nevirapine</td>
<td>0.543 +/− 0.054</td>
<td>0.669 +/− 0.114</td>
<td>0.867 +/− 0.145</td>
<td>0.508 +/− 0.345</td>
</tr>
<tr>
<td>Raltegravir</td>
<td>1.072 +/− 0.162</td>
<td>0.091 +/− 0.016</td>
<td>0.024 +/− 0.003</td>
<td>0.096 +/− 0.027</td>
</tr>
</tbody>
</table>

*Mean 90% effective concentration ± the standard error from n = 4 independent assays.

### Table 4. HIV-1 inhibitory activity of ARVs in PFA compared to MDM and PBMCs.

<table>
<thead>
<tr>
<th>ARV</th>
<th>PFA compared to MDM</th>
<th>EC50</th>
<th>EC90</th>
<th>PFA compared to PBMC</th>
<th>EC50</th>
<th>EC90</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Δ</td>
<td>p</td>
<td></td>
<td>Δ</td>
<td>p</td>
<td></td>
</tr>
<tr>
<td>Lamivudine</td>
<td>8.8</td>
<td>0.0079</td>
<td>63</td>
<td>1.0</td>
<td>0.4524</td>
<td>4.3</td>
</tr>
<tr>
<td>Stavudine</td>
<td>142</td>
<td>0.0079</td>
<td>382</td>
<td>33</td>
<td>0.0079</td>
<td>18</td>
</tr>
<tr>
<td>Zidovudine</td>
<td>262</td>
<td>0.0070</td>
<td>202</td>
<td>164</td>
<td>0.0048</td>
<td>92</td>
</tr>
</tbody>
</table>

Δ, fold change in EC50 or EC90 values.
P values (p) were determined using a non-parametric Mann Whitney U-test. Values < 0.05 were considered statistically significant.
PFA, primary fetal astrocytes; PBMC, peripheral blood mononuclear cells; MDM, monocyte-derived macrophages.
physiological concentration ranges in the CSF and plasma, respectively. These results suggest that there may be insufficient levels of 3TC, d4T and ZDV to inhibit HIV-1 infection of astrocytes in vivo, but that these drugs are likely to retain sufficient antiviral activity in the macrophage-lineage cellular compartments of the CNS.

**Discussion**

Our results suggest that certain CNS penetrating ARVs used in Neuro-cART regimens may not be effective against HIV-1 infection of astrocytes. 3TC, ZDV and d4T are used in Neuro-cART regimens [8,22], but here we show that the concentration of these drugs required to achieve virological suppression in astrocytes is 12-, 110, and 187-fold higher than what is achievable in the CSF, respectively. In contrast, 3TC, ZDV and d4T achieved virus inhibition in PBMC and MDM at concentrations that were below or within the respective concentration ranges that are achieved in vivo. Our results suggest that these NRTIs may not target all the susceptible HIV-1 target cell populations in the CNS, with potential implications for their inclusion in Neuro-cART regimens.

We observed some discordance in EC50 and EC90 values between the astrocyte cell line and primary fetal astrocytes. This highlights some of the limitations of using SVG for astrocyte work and reinforces the need to use the ‘gold standard’ PFA for confirmatory studies. In addition, while the EC50/EC90 values generated here are useful and insightful, they were generated in the context of a single round of infection. Therefore, further studies are required to analyze ARV effectiveness in the context of multiple rounds of infection.

Our recent studies showed that up to approximately 20% of astrocytes can be infected with HIV-1 in vivo, and therefore astrocytes represent a potentially significant reservoir of HIV-1 in the CNS [6]. Astrocytes are critical for maintaining normal brain homeostasis [23] and astrocyte dysfunction is known to contribute to HIV-1 neuropathogenesis [1,4]. Continuing to use Neuro-cART regimens containing 3TC, d4T or ZDV could potentially lead to astrocyte infection remaining untargeted, which may contribute to neurocognitive impairment despite virological suppression in plasma. In support of this possibility, the prevalence of HAND is increasing despite suppressive cART [24–27].

The current focus on HIV-1 cure and eradication strategies has identified persistently infected viral reservoirs as a major barrier to the successful elimination of the virus [28–30]. These viral reservoirs are located within the brain, gut-associated lymphoid tissue, bone marrow, and genital tract [31]. HIV-1 infection of astrocytes is predominantly restricted to the expression of genes encoding the regulatory/accessory HIV-1 proteins [32], some of which are neurotoxic (for example the HIV-1 Tat protein) [33], and contributes to the persistent viral reservoir within the brain that is not cleared by the immune system or ARVs [29]. Confirming that the ARVs used in Neuro-cART regimens are active against-, and are present at concentrations sufficient for virological suppression in astrocytes may be important for controlling this potentially significant viral reservoir, and may be necessary to prevent the transcription of HIV-1 genes encoding neurotoxic viral proteins. The optimal targeting of HIV-1 infected astrocytes by ARVs may prevent the expansion of this HIV-1 infected cellular reservoir and potentially aid virus eradication efforts, and may also potentially contribute to better treatment outcomes by reducing neurotoxicity.

While we have shown that both ZDV and d4T have markedly reduced effectiveness in astrocytes compared to macrophages, the underlying mechanism for this remains unknown. All the NRTIs tested here require activation from their inactive native form by three sequential phosphorylation events. In the case of ZDV and d4T, the un-phosphorylated form is converted to the mono-, di- and tri-phosphorylated forms by the cellular thymidine kinases, thymidylate kinase and deoxynucleoside diphosphate kinase, respectively [34]. In contrast, 3TC (whose reduced HIV-1...
inhibitory activity in astrocytes is relatively modest compared to that of d4T and ZDV) and ABC only have the final phosphor-
dication event in common, indicating unique cellular kinases are involved in their initial phosphorylation events. The drug is only active against the HIV-1 reverse transcriptase once the drug is tri-
phosphorylated by competing with the natural dNTP substrate for
incorporation into DNA and causing chain termination. Three possible explanations could address the reduced effectiveness of
d4T and ZDV in astrocytes; differences in cellular uptake of
NRTIs, inefficient or incomplete drug activation (due to lower
levels of cellular kinases or competition with the natural substrates
for the kinases), and inefficient incorporation into DNA (due to
higher levels of endogenous nucleotides). To this end, Perno
et al. demonstrated that ZDV was more potent against HIV-1 infection
in macrophage lineage cells due to lower levels of competing
endogenous thymidine [35], which is a finding that is supported by
our experiments when comparing EC90 values of ZDV between
PBMC and MDM. Future work will explore this area to better
understand the underlying cause of the markedly reduced effectiveness of
the d4T and ZDV NRTI thymidine analogues in astrocytes.

In conclusion, the results of our study show that certain NRTIs,
in particular the thymidine analogues ZDV and d4T (and to a
lesser degree 3TC) have reduced HIV-1 inhibitory astrocytes
in vitro compared to macrophage-lineage cells, and furthermore that
the inhibitory concentrations of 3TC, ZDV and d4T in astrocytes
exceed those achievable in the CSF. Thus, Neuro-cART regimens
containing ZDV, d4T and/or 3TC may not effectively target
HIV-1 infected astrocytes of the CNS. Furthermore, our results
are the first to show differential ARV efficacy in brain cells, thereby
introducing an important principle in the future analysis of
ARVs.

Acknowledgments

We thank Eugene Major for supplying the SVG cell line. ARVs were
obtained through the NIH AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH.

Author Contributions

Conceived and designed the experiments: LRG GT PRG MJC. Performed
the experiments: LRG AME MJR WC. Analyzed the data: MJC GT PRG.
Contributed reagents/materials/analysis tools: GG BJB SGT SLW. Wrote
the paper: LRG PRG MJC.

References

microglia express CD14 and CD45 and are productively infected by HIV-1 in
capture microdissection to detect integrated HIV-1 DNA in macrophages and
Astrocyte infection by HIV-1: mechanisms of restricted virus replication, and
473.
Extensive astrocyte infection is prominent in human immunodeficiency virus-
human immunodeficiency virus type 1 on astrocyte gene expression and
Validation of the CNS Penetration-Effectiveness rank for quantifying antiret-
Time-to-Loss-of-Viral-Response in CSF and Plasma in the CHARTER Cohort.
17th Conference on Retroviruses and Opportunistic Infections (CROI). San
Francisco, CA, USA.
of cognitive change in impaired HIV-positive patients initiating antiretroviral
combination antiretroviral therapy on cerebrospinal fluid HIV RNA and
complications of HIV disease and their treatment. Topics in HIV
13. Major EO, Traub RG (1986) JC virus infection during productive infection in
Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal
and functional analysis of R5×4 human immunodeficiency virus type 1 envelope
glycoproteins derived from two individuals homozygous for the CCR5Δ32
gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope
glycoprotein variants with patients with AIDS. Retrovirology 4: 89.
antibodies against primary human immunodeficiency viruses by soluble
Structure activity relationship of dendrimer microparticles with dual action
Tropism of Human Immunodeficiency Virus Type 1 Isolates from Brain and
Lymphoid Tissues Predicts Neurotropism Independent of Co-receptor Specific-
Selection for a Nucleoside Reverse Transcriptase Inhibitor through Use of
Population Pharmacokinetic Modeling and Monte Carlo Simulation. Antimi-
 crobial agents and chemotherapy 46: 913–916.
influencing the emergence of resistance to indinavir: role of virologic,
immunologic, and pharmacologic variables. The Journal of infectious diseases
170: 360–367.
are neurologically active drugs important? Arch Neurol 61: 1699–1704.
23. Volterra A, Meldolesi J (2005) Astrocytes, from brain glue to communication
in survival following AIDS dementia complex in the era of highly active
antiretroviral therapy. AIDS 17: 1539–1545.
25. Heaton RK, Clifford DB, Franklin DR, Jr., Woods SP, Ake C, et al. (2010) HIV-
associated neurocognitive disorders persist in the era of potent antiretroviral
Continued high prevalence and adverse clinical impact of human immuno-
deficiency virus-associated sensory neuropathy in the era of combination
HIV-associated neurocognitive disorders before and during the era of
combination antiretroviral therapy: differences in rates, nature, and predictors.
J Neurovirol 17: 3–16.
virus. Proceedings of the National Academy of Sciences of the United States of
America 96: 10958–10961.
614.
HIV persistence and the prospect of long-term drug-free remissions for HIV-
patients receiving potent antiretroviral combination therapy. JAMA: the